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ORIGINAL ARTICLE
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ABSTRACT
Introduction: Spontaneous preterm delivery (<37 gestational weeks) has a multifactorial eti-
ology with still incompletely identified pathways. Amniotic fluid is a biofluid with great potential
for insights into the feto-maternal milieu. It is rich in metabolites, and metabolic consequences
of inflammation is yet researched only to a limited extent. Metabolomic profiling provides
opportunities to identify potential biomarkers of inflammatory conditioned pregnancy complica-
tions such as spontaneous preterm delivery.
Objective: The aim of this study was to perform metabolomic profiling of amniotic fluid from
uncomplicated singleton pregnancies in the mid-trimester to identify potential biomarkers asso-
ciated with spontaneous preterm delivery and gestational duration at delivery. A secondary aim
was to replicate previously reported mid-trimester amniotic fluid metabolic biomarkers of spon-
taneous preterm delivery in asymptomatic women.
Method: A nested case-control study was performed within a larger cohort study of asymptom-
atic pregnant women undergoing mid-trimester genetic amniocentesis at 14–19 gestational
weeks in Gothenburg, Sweden. Medical records were used to obtain clinical data and delivery
outcome variables. Amniotic fluid samples from women with a subsequent spontaneous pre-
term delivery (n¼ 37) were matched with amniotic fluid samples from women with a subse-
quent spontaneous delivery at term (n¼ 37). Amniotic fluid samples underwent untargeted
metabolomic analyses using liquid chromatography-mass spectrometry. Multivariate random for-
est analyses were used for data processing. A secondary targeted analysis was performed, aim-
ing to replicate previously reported mid-trimester amniotic fluid metabolic biomarkers in
women with a subsequent spontaneous preterm delivery.
Results: Multivariate analysis did not distinguish the samples from women with a subsequent
spontaneous preterm delivery from those with a subsequent term delivery. Neither was the
metabolic profile associated with gestational duration at delivery. Potential metabolic biomarker
candidates were identified from four publications by two different research groups relating mid-
trimester amniotic fluid metabolomes to spontaneous PTD, of which fifteen markers were
included in the secondary analysis. None of these were replicated.
Conclusions: Metabolomic profiles of early mid-trimester amniotic fluid were not associated
with spontaneous preterm delivery or gestational duration at delivery in this cohort.
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Introduction
The spontaneous onset of labor, both at term (delivery
at or after 37weeks of gestation) and at preterm
(delivery before 37weeks of gestation), is multifactor-
ial, complex and not completely understood. Several
mechanistic factors initiate maternal-fetal inflammatory
processes [1–3] that stimulate the production and
expression of cytokines and cytotoxic molecules with
subsequent uterine activity [4]. This inflammation can
alter the local and systemic metabolic profile [5].
Examining interactions between inflammation and
metabolic changes during gestation using metabolo-
mics (comprehensive measurement of small molecule
metabolites in a biological sample) may thereby
increase our understanding of the etiology of spontan-
eous preterm delivery (PTD), and gestational duration
at delivery [5]. It is also a promising method for bio-
marker discovery [6,7], where especially amniotic fluid,
rich in metabolites, becomes a highly interesting bio-
logical matrix [5].
The number of studies using metabolomics analy-
ses for biomarker research has increased substantially
during the last years. A few studies have used metab-
olomics to identify biomarkers of spontaneous PTD in
amniotic fluid from symptomatic women, with either
spontanteous preterm labor with intact membranes
(PTL) or preterm prelabor rupture of membranes
(PPROM), in the late second or third trimester [8,9].
They found that higher levels of amino acids, unsatur-
ated hydroxyl fatty acids and fatty aldehydes [8], i.e.
products of the intermediate metabolism of mamma-
lian cells and xenobiotic compounds, were associated
with spontaneous PTD [9]. However, only a limited
number of studies have performed metabolic profiling
of mid-trimester amniotic fluid in relation to spontan-
eous PTD in asymptomatic women [7,10–12], of which
the majority include a small number of subjects and a
very broad sampling window. The identification of
early biomarkers in yet asymptomatic women may be
of greater value since these could predict women at
risk of spontaneous PTD.
The aim of this study was to investigate metabolo-
mic profiles of mid-trimester amniotic fluid obtained
from asymptomatic women and to examine associa-
tions with a subsequent spontaneous PTD and gesta-
tional duration at delivery. Second, the study aimed to
replicate previously reported mid-trimester amniotic
fluid metabolite biomarkers associated with spontan-
eous PTD.
Material and methods
Inclusion and exclusion criteria
Women 18 years of age with a singleton pregnancy,
intact membranes and without signs of infection who
underwent a mid-trimester genetic amniocentesis at
Sahlgrenska University Hospital/€Ostra, Gothenburg,
Sweden were recruited to a large prospective preg-
nancy cohort study. Women enrolled between
September 2008 and July 2017 were selected for this
nested case-control study. Amniocentesis was per-
formed between 14 and 19weeks of gestation in line
with clear clinical indications: advanced maternal age
(35 years), first trimester combined screening indicat-
ing a high risk of chromosomal abnormality, family
history of chromosomal abnormalities or genetic dis-
eases, or anxiety. Women who had multiple preg-
nancy, infection with human immunodeficiency virus,
hepatitis B or C virus and women with known or sus-
pected fetal abnormalities were considered ineligible
as well as women undergoing amniocentesis during
times when study samples could not be collected.
Women who could not provide an informed consent
in Swedish, who declined participation, who had an
initial twin gestation with vanishing twin, or where an
insufficient amount of amniotic fluid was collected
were excluded.
Selection of cases and controls
Medical records were used to obtain subjects’ demo-
graphics and clinical data. Women with a subsequent
spontaneous PTD (cases) were matched to women
with a subsequent delivery at term (controls) on a 1:1
ratio. The group of women with a spontaneous deliv-
ery at term was limited to gestational weeks
38þ 0–41þ 6 to achieve a more homogeneous group.
Matching was performed according to the following
criteria; (1) gestational age at sampling (±3 days), (2)
parity (nulliparous/multiparous), (3) in vitro fertilization
(IVF; yes/no), (4) maternal age at sampling (±2 years),
(5) body mass index (BMI) group (according to the
World Health Organization (WHO) definitions of BMI
categories: underweight (<18.5 kg/m2); normal weight
(18.5–24.9 kg/m2); pre-obesity (25.0–29.9 kg/m2); obes-
ity class I (30.0–34.9 kg/m2) and obesity class II
(35.0–39.9 kg/m2)), and (6) pregnancy complications or
maternal chronic diseases. Women who fulfilled the
above-described criteria and who had the closest sam-
pling dates to the cases were selected as controls.
Matching was successful with a few exceptions where
e.g. the criteria of BMI category could not be matched
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and where the matching was instead based on the
actual BMI value.
Collection and processing of samples
Amniotic fluid samples for research (approximately
3ml) were collected during the clinical mid-trimester
genetic amniocentesis. The procedure was ultrasound-
guided, transabdominal, and performed using a 22-
gauge needle. Immediately after withdrawal, samples
were stored at 4–8 C for 4 ± 1.9 h (mean± SD) before
centrifugation for 20min at 12,000 g, 4 C.
Supernatants and pellets were thereafter separated,
aliquoted, frozen and stored at 80 C awaiting ana-
lysis. Parts of the larger prospective pregnancy cohort
study have previously been used for a few different
subset analyses [13–15].
Ethical approval
The study was approved by the Ethics Review Board
at the University of Gothenburg, Sweden (Dnr. €O 639-
03, T 318–08, T 694-11, 2019-06022). All participants
had given their written informed consent.
Untargeted LC-MS metabolomics
Amniotic fluid samples were analyzed by untargeted
UHPLC-QTOF metabolomics at the Chalmers Mass-
Spectometry Infrastructure at Chalmers University of
Technology. In brief, samples were thawed at 4 C and
a 30lL aliquot was mixed with 200 lL cold (4 C)
acetonitrile on a 96 well plate. The plate was sealed,
mixed using an orbital shaker and centrifuged for
10min at 500 g (4 C). The remaining supernatants
were then filtered through 0.2 lm Captiva ND plates
(Agilent Technologies) onto a 96 well plate.
The samples were analyzed using both reverse
phase and HILIC chromatography on an Agilent 1290
Binary LC system coupled to an Agilent 6550 quadru-
pole time-of-flight mass spectrometer with electro-
spray ionization operated both in positive and
negative ionization. For reverse phase, sample extracts
were kept at 4 C and injected onto a Waters Acquity
UPLC HSS T3 column (2.1 100mm, 1.8 lm), main-
tained at 45 C. Mobile phases were ultrapure water
(A) and LC-MS grade methanol, both containing 0.04%
formic acid, and a linear gradient from 5% to 100% B
over 6min were used for sample elution. Flowrate was
set to 0.4ml/min. For HILIC chromatography, a Waters
Acquity UPLC BEH Amide NH2 column (100 2.1mm,
1.7 lm), maintained at 45 C, was used and mobile
phases were water (A) and 90/10 acetonitrile/water
(B), both with 10mM ammonium formate at pH 3.5.
The gradient started at 100% B where held for 1min,
ramped to 70% B over 7min and returned to initial
conditions after 0.1min. Flowrate was set to 0.4ml/
min. Mass spectra were acquired across a mass range
of 50–1600m/z at 1.67 spectra/second. The capillary
voltage was set at 3500 V. The source parameters were
set with gas temperature at 175 C, flow at 12 L/min,
nebulizer at 45 psig, sheath gas at 350 C and sheat
gas flow at 11 L/min. MS data were acquired with
Mass Hunter Workstation Data Acquisition (Agilent
Technologies).
Pre-processing pipeline
Raw centroid instrument files were converted to
.mzML file format using the MSConvertGUI software
[16] before being imported into the R v3.5.1 open
source environment [17]. The XCMS v3.4.4 package
was used for peak picking, retention time alignment,
grouping and filling of missing features [18]. XCMS
parameters were optimized using a combination of
the IPO v1.8.1 package [19] and manual optimization
performed on all QC samples spanning the entire
injection sequence (Table S1). Imputation of values still
missing after XCMS peak filling was performed using
an in-house RandomForest-based algorithm (https://
gitlab.com/CarlBrunius/StatTools; mvImpWrap() func-
tion). The obtained data were corrected for within-
and between-batch intensity drift using the batchCorr
package [20], after which features with high variability
among QC samples (RSD > 30%) were filtered out.
Finally, grouping of features (isotopes, adducts and
fragments) corresponding to the same metabolites
was achieved using the RAMClustR package [21]. The
similarity parameters (rt, rr) were optimized using an
in-house procedure. The number of features per LC-
MS mode at key steps of the pre-processing pipeline
is reported in Table S1. R scripts for parameter opti-
mization and pre-processing are available from the
authors upon request.
Targeted LC-MS metabolomics
In the secondary analysis, targeted analyses were per-
formed on metabolite biomarkers previously reported
in mid-trimester amniotic fluid of asymptomatic
women, as being associated with the subsequent
development of spontaneous PTD. Metabolite bio-
markers in amniotic fluid of symptomatic women (PTL
or PPROM, with or without signs of inflammation or
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infection) in the late mid-trimester were not included
due to the high likelihood that these would reflect dif-
ferent biological mechanisms.
Investigation of the reported biomarker candidates
from the literature was performed in the collected
data by extracting features corresponding to a short-
list of adducts for the suggested neutral masses
([MþH]þ, [MþNa]þ, [Mþ K]þ, [MþNH4]þ,
[MþCH3OHþH]þ, [MþACNþH]þ and [Mþ 2H]2þ in
positive mode and [MH], [MH2OH], [MþNa
 2H], [Mþ K 2H], [MþCl], [Mþ FAH],
[MþHAcH] and [M 2H]2 in negative mode)
within a mass difference of 10 ppm. Significance of
association was assessed using paired t-tests between
case/control pairs. Features not matching the sug-
gested candidates were filtered out, first by MS (if e.g.
matching to an isotope instead of main fragment) and
later by MSMS by comparing fragmentation patterns
to HMDB hits of the suggested biomarker candidates.
Statistical analysis
Differences in baseline characteristics between cases
and controls were analyzed by Mann–Whitney U test
and presented as median (interquartile range (IQR)) for
continuous variables while categorical data were ana-
lyzed by Chi-square test or Fishers exact test (when
below five individuals at any level) and presented as
numbers [frequency distribution (%)], using SPSS 24.0
and 25.0 for Windows XP (SPSS Inc., USA). Differences
were considered statistically significant at p< .05 using
a two-sided alternative hypothesis.
To establish that the metabolomics data was fit
for purpose (sanity check), we first investigated the
association between metabolome and gestational
age at sampling (not related to the study aims). In
the primary analysis, we investigated the associations
of the mid-trimester amniotic fluid metabolome with
both spontaneous PTD and gestational duration at
delivery. Multivariate analysis for both sanity check
and primary analysis was performed using random
forest with unbiased variable selection within
repeated double cross-validation, using the MUVR R
package v 0.0.973 [22]. Analysis of spontaneous PTD-
vs-control was investigated as case/control pair-
dependent multilevel analyses using log fold change
between cases and controls as independent variables
[22–24]. Random forest regression models using
MUVR were performed for the association of the
amniotic fluid metabolome with gestational age at
sampling and gestational duration at delivery.
Statistical significance of multivariate models was
assessed using permutation tests [25] and consid-
ered significant at one-sided p< .05 (i.e. actual
model performing better than permuted null
hypothesis distribution).
Results
Characteristics of the study population
During the study period, 3128 women underwent
genetic amniocentesis. Of these, 1218 women
(38.9%) were enrolled, 762 women (24.4%) were
ineligible and 1148 women (36.7%) were excluded,
the majority of which declined participation. Of the
1218 enrolled women, 28 had a termination of preg-
nancy due to chromosomal abnormalities, 7 were
lost to follow-up, 3 had a miscarriage and 16 were
incorrectly enrolled (blood borne viral infection, sus-
pected fetal abnormalities or initial twin gestation
with fetal demise of one twin or with vanishing
twin). These were excluded, leaving 1164 women to
constitute the selection group for cases and controls.
PTD occurred in 6.4% of the women (75/1164), of
which 68.0% (51/75) were spontaneous PTD, includ-
ing women with PTL (n¼ 25) and women with
PPROM (n¼ 26). Further, women with medically indi-
cated onset of labor, both at term and preterm
(n¼ 294), were excluded, leaving 870 women with a
spontaneous onset of labor at term or preterm for
the selection of spontaneous cases and controls.
Protocol deviations in process handling or sampling
deviations (discolored amniotic fluid due to blood
contamination) occurred in a few cases (n¼ 4) and
these were thus excluded. Women with severe
chronic diseases or conditions that could potentially
contribute to the occurrence of spontaneous PTD or
affect the metabolome, such as uterus malforma-
tions, polycystic ovary syndrome, diabetes mellitus,
gestational diabetes or malignity (n¼ 6), and women
with confirmed or suspected maternal or fetal gen-
etic abnormalities (n¼ 4) were also excluded, leaving
37 women with a spontaneous PTD. These were
matched to an equal number of controls (n¼ 37).
One case sample was lost during the analysis due
to instrument malfunction, leaving 36 matched case/
control pairs (n¼ 72) for the statistical analyses
(Figure S1).
Maternal and neonatal characteristics of the 36
cases and matched controls are presented in
Table 1. There were no significant differences
between the groups except the obvious difference
in gestational duration at delivery and neonatal birth
weight.
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Primary analysis by untargeted
metabolic profiling
Data integrity was assessed by regressing the gesta-
tional age at sampling on the measured amniotic fluid
metabolome (the model’s predictive ability (Q2) ¼
0.22, p¼ .00018). There was no association in the
multilevel random forest analysis between the metab-
olomic profile of mid-trimester amniotic fluid and
spontaneous PTD (classification rate (CR) 51%). Nor,
any associations were found in regards to gestational
duration at delivery (Q2 ¼ 0.03).
Secondary analysis by targeted
metabolic profiling
Four studies by two different research groups relat-
ing mid-trimester metabolomes to spontaneous PTD
were identified [7,10–12], providing 32 potential bio-
marker candiates. However, m/z values of all the ten
metabolites identified by Graça et al. [7] and seven
of the metabolites identified by Virgiliou at el. [12]
were either metabolite fragments, metabolite
adducts, newly identified metabolite variations or
unknown features and reported with only two deci-
mals resolution. They were thus unsuitable for
matching to exact mass and were consequently not
included in the secondary analysis, leaving three
studies and 15 metabolites for replication using tar-
geted metabolomics (Table 2). None of these metab-
olites were associated with spontaneous PTD in our
dataset at nominal p< .05.
Discussion
This study aimed to identify potential biomarkers for
spontaneous PTD, using metabolomic profiling of early
mid-trimester amniotic fluid from asymptomatic
women. It further aimed at investigating the associ-
ation between the early amniotic fluid metabolomic
profiling and gestational duration at delivery. We
employed advanced multivariate prediction models
with reduced risk of overfitting [22,26]. The metabolo-
mic profile did not associate with either spontaneous
PTD or gestational duration at delivery, indicating that
biological signals in amniotic fluid collected at early
mid-trimester may be of insufficient strength for accur-
ate risk predictions of spontaneous PTD and gesta-
tional duration at delivery at the individual level. The
metabolomic profile did, however, correlate to gesta-
tional age at sampling, indicating that the amniotic
fluid, at least partly, reflect the biological process of
pregnancy development. Such “pregnancy clocks”
have previously been reported using different omics
techniques [27–31]. In the secondary analysis, we
aimed to replicate previously reported amniotic fluid
metabolites associated with spontaneous PTD in
asymptomatic women with singleton pregnancies in
the mid-trimester. None of the 15 potential metabolic
candidate biomarkers from previous studies [10–12]
were associated with spontaneous PTD in our dataset.
Spontaneous PTD is a complex, heterogenous con-
dition where several pathophysiological mechanisms,
such as inflammation, infection, oxidative stress and
placental dysfunction, have been proposed. Previous
studies using metabolomics on mid-trimester amniotic
Table 1. Characteristics of cases with spontaneous PTD and matched controls.
Variable Spontaneous PTD (n¼ 36) Controls (n¼ 36) p
Gestational duration at delivery (weeksþ days) 36þ 1 (33þ 5–36þ 4) 39þ 6 (38þ 6–40þ 5)
Birth weight (grams) 2643 (2199–3018) 3587 (3280–3974)
Matching variables
Gestational age at sampling (weeksþ days) 15þ 5 (15þ 0–16þ 1) 15þ 4 (15þ 2–16þ 0) .92
Nulliparous 13 (36.1%) 12 (33.3%) .80
IVF 3 (8.3%) 3 (8.3%) 1.00
Maternal age at sampling (years) 37 (35–39) 37 (35–39) .74
Maternal BMI at first prenatal visit 25.6 (22.7–28.1) 25.8 (22.2–27.7) .99
Other variables
Smoking at first prenatal visit 3 (8.3%) 0 (0.0%) .24
Previous PTD 5 (13.9%) 5 (13.9%) 1.00
Mode of delivery
Vaginal delivery 27 (75.0%) 30 (83.3%) .38
Vacuum extraction or forceps 1 (2.8%) 3 (8.3%) .61
Cesarean section 8 (22.2%) 3 (8.3%) .19
Neonatal sex .64
Male 15 (41.7%) 17 (47.2%)
Female 21 (58.3%) 19 (52.8%)
Apgar score <7 at 5min 1 (2.8%) 0 (0%) 1.00
Continuous variables were analyzed using a Mann-Whitney U Test and are presented as the median (IQR). Categorical variables were analyzed using
Pearson Chi-Square or Fisher’s Exact Test (when the expected values in any of the cells are below five individuals) and are shown as N (%). Bold text
indicate statistical significance at p< .05 using a two-sided alternative hypothesis.
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fluid [7,10] have found decreased levels of several
amino acids in spontaneous PTD cases. As amino acids
are transported between the maternal and fetal circu-
lation by the placenta, their findings corroborate that
disturbances in placental function may play a role in
the spontaneous PTD etiology [32]. Increased levels of
allantoin, a metabolic intermediate produced from uric
acid, previously described as a potential marker of oxi-
dative stress, has also been found in spontaneous PTD
cases [10].
Apart from the studies on asymptomatic women
[7,10–12], there are also studies describing the metab-
olomic profiles of term and preterm cases sampled
when labor has already commenced. Menon et al. [33]
identified several altered amniotic fluid metabolites in
spontaneous PTD, a majority of them linked to liver
function and fatty acid metabolism. Fatty acids were
also found to differ between study groups in the
study by Lizewska et al. [34], not between the term
and preterm group, but between women who deliv-
ered preterm and women with threatening preterm
labor who went on to deliver at term. Romero et al.
[9] report an association between the presence of
intra-amniotic inflammation (IAI) and an altered amni-
otic fluid metabolite composition. Carbohydrates
(mannose, galactose and fructose) were relatively
increased in patients with PTL who delivered at term
while amniotic fluid amino acids (alanine, glutamine
and glutamic acid) were decreased, with the opposite
state in patients with PTL and IAI.
Comparing results from metabolomics studies of
symptomatic women with results from studies of
asymptomatic women is problematic for several rea-
sons. First, the origin and composition of amniotic
fluid changes with advancing gestational age [35].
Second, metabolic adaptions to support the growing
fetus occur during pregnancy. Early gestation is char-
acterized by an anabolic state, where lipids are stored
and insulin sensitivity increased, compared to late ges-
tation which should rather be considered a catabolic
phase [36]. Third, amniotic fluid samples from women
with threatening PTD represent cases where the con-
dition is already in its most advanced stagesand may,
therefore, express other markers than those present in
the early stages.
Spontaneous PTD has been heavily linked to inflam-
mation, both infection-mediated and sterile, and ele-
vated levels of prostaglandins, key mediators in the
inflammatory response, have been demonstrated in
amniotic fluid in women with PPROM, regardless the
presence of infection [37]. Prostaglandins are derived
from the fatty acid arachidonic acid. In the presence
of inflammation leading to elevated concentrations of
prostaglandins, one would expect to find altered levels
of its fatty acid precursor. However, in our cohort, the
majority of women had late PTD where infection and
inflammation are less frequently involved [38], making
it less likely to find such patterns.
Several factors may contribute to the discrepancy
between our study and previous studies on asymp-
tomatic women [7,10–12]. The sampling of previous
studies occurred within a broader gestational age
interval compared to our study which rather reflects
early mid-trimester. Metabolic changes appear during
Table 2. Metabolites included in the secondary analysis.
Metabolite HMDB identifier Monoisotopic massa
Regulation in spontaneous PTD
(effect size cases vs controls) Publication p Commentary
Alanine 161 89.05 Decrease (7%) [10] .003 NS
Alanine 161 89.05 N/A [11] N/A NS
Alfa-oxoisovalerate 0019 116.05 Decrease [11] N/A NS
Allantoin 0462 158.04 Increase (47%) [10] .002 NS
Citrate 0094 192.03 Decrease (6%) [10] 0.005 NS
Citrate 0094 192.03 N/A [11] N/A NS
Glucose 0122 180.06 Decrease [11] N/A NS
Glutamic acid 014 147.05 Increase [12] N/A NS
Histidine 0177 155.07 N/A [11] N/A NS
Inositol/myo-inositol 0211 180.06 Decrease (7%) [10,12] .002 NS
Inositol 0211 180.06 Decrease [12] .002 NS
Myo-inositol 0211 180.06 Decrease (7%) [10] .002 NS
Isoleucine/leucine 13,773 N/A Decrease [11] N/A NS
Lysine 3405 146.11 Decrease [11] N/A NS
Phenylalanine 159 165.08 N/A [11] N/A NS
Proline 162 115.06 Decrease [11] N/A NS
Pyruvat 243 88.02 Decrease [12] N/A NS
Tyrosine 158 181.07 Decrease [11] N/A NS
Valine N/A 117.08 N/A [11] N/A NS
aMonoisotopic mass for annotated metabolites from HMDB database.
Commentary reflects the findings in our dataset. NS: not significant; N/A: information not available.
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pregnancy [39], which might partly explain previous
findings being different from ours since their samling
took place up to six weeks later in pregnancy. In all
studies of Graça et al. [7,10,11], the number of sam-
ples were limited (n¼ 11–14) and women were of a
broad age range (13–42 years). Our sample size was
threefold larger and more homogenous in regards to
gestational age at sampling, as previously mentioned,
but also in regard to maternal age. It is known that
maternal age and lifestyle factors may affect metabolic
profiles and it is possible that our cohort and those of
previous studies may be of significant biological differ-
ence. In a systematic review from 2019 using metabo-
lomics to identify pathways and biomarkers of PTD
[40], Carter et al. concluded that there is an inconsist-
ency in study design and methodology in regard to
biological samples, definition of the outcome, con-
founding factors and covariates, and metabolite identi-
fication. Highly heterogenous studies, together with
potential internal and external factors, unknown to us
at this time, can further contribute to the discrepancy.
Several of the previously reported metabolites asso-
ciated with spontaneous PTD were related to energy
and amino acid metabolism [7,12]. Many of these are
affected by sample management such as pre-centrifu-
gation temperature and time [41]. It is, therefore, pos-
sible that the variability in pre-centrifugation time in
the present study could have obfuscated true underly-
ing associations of spontaneous PTD with these
metabolites or, alternatively, that the previous report-
ing of these metabolite candiates may in fact be arte-
factual. Although we cannot arbiter between these
potential options, we have reason to believe that the
data integrity in our study is fundamentally sound,
from the sanity check of being able to model gesta-
tional age at sampling. In the study of Graça et al. [7],
samples were centrifuged after sampling, as in our
study, but using slightly different conditions. In the
study of Virgiliou et al. [12], samples were frozen
immediately after collection and later thawed and
processed. There was, however, no information about
preparation time or storage temperature during prep-
aration. Further, the results from Graça et al. [10]
revealed only small metabolite changes in a very lim-
ited sample size. In a study from the same group in
2013 [11], mid-infrared spectroscopy was used, a tech-
nique that report chemical classes rather than individ-
ual metabolites. Results should, therefore, be
interpreted with caution, as the authors also state.
The major strengths of this study are the unique
cohort of mid-trimester amniotic fluid samples from
asymptomatic women, a very low proportion of lost to
follow-up, an extensive database with clinical variables
and thorough selection criteria for cases and controls.
Another strength is the use of a validated and estab-
lished pipeline for comprehensive coverage of the
metabolomic profile using untargeted metabolomics.
Finally, we employed a robust data processing pipe-
line using a random forest implementation designed
to minimize overfitting and false positives.
Potential limitations are that the spontaneous PTD
group consisted of women with both PTL and PPROM,
where the respective phenotypes may differ. The
prevalence of PTD in Sweden is only 5.6% [42] and
despite a relatively large cohort, the sample size did
not allow differentiation. Further, women undergoing
genetic amniocentesis are often of a more advanced
maternal age and have a higher risk of fetal chromo-
somal abnormalities than the overall population,
decreasing generality. However, due to the risks with
such invasive sampling, mid-trimester amniotic fluid
samples for research can only be performed in con-
junction with a clinical procedure. A criterion for
enrollment was that the women understood the writ-
ten and oral information about the study, provided in
Swedish. Enabling women with other languages to
participate could potentially have given us other
results since it, most likely, would have increased our
population size, and since it is recognized that both
the spontaneous PTD rate and the metabolome differs
between ethnicities. Another important limitation is
the diversity in sample preparation time which may
have affected the ability to identify potentially import-
ant but not as stable markers. Further, the study
design using matched cases and controls was not
optimal from a gestational duration at delivery per-
spective, limiting the likelihood of discovering associa-
tions for such a continuous variable. Finally, sampling
only occurred once during gestation and within a very
limited time frame of pregnancy (14–19 gestational
weeks). Sampling at later gestational ages might have
led to other results, however, this can only be specu-
lated on. This is neither anything that we can influ-
ence in a cohort of asymptomatic women like this
one, as such samples are scarce and collected in
accordance with clinical routine where amniocentesis
is used very restrictively in Sweden.
Conclusions
Our results do not provide evidence that the meta-
bolic profile in the early mid-trimester amniotic fluid is
associated with either spontaneous PTD or gestational
duration at delivery. Possibly, biological signals in early
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mid-trimester amniotic fluid may be of insufficient
strength for accurate risk predictions of spontaneous
PTD and gestational duration at delivery at the indi-
vidual level.
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